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MicroRNAs (miRNAs), a class of small, non–protein-cod-
ing transcripts about 21 nucleotides long, have recently
entered center stage in the study of posttranscriptional
gene regulation. They are now thought to be involved in
the control of about one third of all protein-coding genes
and play a role in the majority of cellular processes that
have been studied. We focus on the role of the miRNA
pathway in brain development, function, and disease by
highlighting recent observations with respect to miRNA-
mediated gene regulation in neuronal differentiation,
synaptic plasticity, and the circadian clock. We also dis-
cuss the implications of these ﬁndings with respect to the
involvement of miRNAs in the etiopathology of brain dis-
orders and pinpoint the emerging therapeutic potential of 
miRNAs for the treatment of human diseases.
Introduction
MicroRNAs (miRNAs) are small noncoding RNAs that
regulate gene expression at the posttranscriptional level
through sequence-specific base pairing with a target 
mRNA. Originally discovered in the nematode Caenorhab-
ditis elegans in 1993 [1], lin-4, the first identified miRNA, 
was deemed an oddity peculiar to the worm until 7 years
later, when the second miRNA found in C. elegans (let-
7) was shown to be conserved in both sequence and the 
expression pattern during development in a variety of 
organisms [2,3]. Intrigued by the idea that lin-4 and let-7
might indeed be the first members of an abundant class of 
small regulatory RNAs to be discovered, several research
groups started to clone small RNAs from diverse species
and, consequently, hundreds of miRNAs were identified
in worm, fly, and mammalian genomes [4–6]. Since then,
numerous miRNAs have been detected in all multicellu-
lar eukaryotes that have been studied, as well as in a few
viruses. Recently, the discovery of miRNAs in the unicel-
lular algae Chlamydomonas reinhardtii indicated miRNA
pathways as ancient regulatory mechanisms that evolved 
even before the emergence of multicellularity [7,8]. To
date, in miRBase (http://microrna.sanger.ac.uk), the most
carefully curated database of miRNAs with support from
experimental evidence, over 5000 miRNA loci have been
deposited, of which 541 are human (release 10.1). With 
the rapid development of next-generation sequencing tech-
nology and its application in small RNA discovery, the
ongoing identification of new miRNAs is expected to accel-
erate even more in the near future [9,10].
miRNA Biogenesis
A scheme representing the topical concept of miRNA
biogenesis is shown in Figure 1. miRNAs are initially
transcribed by RNA-polymerase II as long transcripts,
often several kilobases in length, and termed pri-miR-
NAs. They are subsequently processed by the RNase III 
enzyme Drosha into approximately 70-nucleotide hairpin
RNAs [11]. Some spliced-out introns in Caenorhabditis
elegans, Drosophila melanogaster, and mammals cor-
respond exactly to pre-miRNAs and therefore do not
require Drosha processing (“mirtons”) [12••]. The hair-
pin precursor miRNAs, called pre-miRNAs, are then
exported from the nucleus to the cytoplasm [13] by the
nuclear export factor exportin-5 in a guanosine-triphos-
phate–dependent manner. In the cytoplasm, they are then
cleaved by Dicer, another RNase III enzyme, into imper-
fect double-stranded RNA duplexes with a 3b overhang of 
two nucleotides [14]. After unwinding of such an RNA
duplex, the strand with lower thermodynamic stability at 
the 5b end (also referred to as guide strand) is incorporated
into a ribonucleoprotein (RNP) complex, called micro-
RNP (miRNP), or miRNA-induced silencing complex 
(miRISC), a multicomponent protein complex responsible
for silencing the target mRNA. The key components of 
miRISC are proteins of the argonaute (AGO) family. In
mammals, four AGO proteins (AGO-1 to AGO-4) are
involved in miRNA-mediated repression. In addition to
AGOs, further regulatory proteins mediating miRISC
function can be part of the complex. An example is the 
fragile X mental retardation protein (FMRP), an RNA-
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binding protein that acts as modulator of translation,
particularly in neurons.
Depending on the degree of complementarity between 
the guide strand and its recognition site in the 3b untrans-
lated region (UTR) of the target, mRNA translation of the
latter is repressed. A perfect match causes mRNA degra-
dation via endonucleolytic cleavage, whereas an imperfect 
match leads to a suppression of protein expression due to
both reduced translation efficiency and increased mRNA
turnover. In animals, most miRNAs form imperfect base
pairing with their binding sites [15]. At present, the molec-
ular mechanism of such repression is still under debate.
Evidence exists for various hypotheses, including inhibition
of eukaryotic translation initiation factor 4E–dependent
translation initiation, inhibition of translation elongation,
premature translation termination, as well as mRNA decap-
ping, deadenylation, and degradation [16–18]. Recently, 
miRNA regulation has gained a new dimension beyond its
role as a translation repressor through the observation that,
although they suppress translation in proliferating cells,
miRNAs can also activate translation upon cell cycle arrest
[19••]. Therefore, it is obvious that there is still much to be 
learned about these small molecules and that we are still at 
an early stage of understanding their importance for cel-
lular differentiation and homeostasis.
miRNA Targets
Elucidation of miRNA function requires the identifica-
tion of target genes, which remains a great challenge for
most miRNAs identified in animals. It has, however, been
shown that the interaction between miRNAs and their
target mRNA in animals is primarily mediated through
six to eight nucleotides in the 5b part of miRNAs, known
as miRNA seeds [20,21]. A diverse array of bioinformatic
approaches has taken advantage of these seed sequences
to predict miRNA targets. Based on bioinformatic predic-
tion, it has been estimated that approximately one third 
of the protein-coding genes in the human genome are
under the control of miRNA regulation [22]. Although
the experimental verification of the targets has advanced
much more slowly, an ever-increasing number of miRNAs 
have already been shown to function in a variety of biolog-
ical processes, including developmental timing, apoptosis,
differentiation, myogenesis, and glucose homeostasis [23].
In the following sections, we focus on the role of miRNAs
in brain function and disease.
miRNA and Brain Function
Since the discovery of the C. elegans lin-4 gene [1,2], our 
understanding of the role of miRNAs in brain develop-
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Figure 1. MicroRNAs (miRNAs) are encoded in the genome. Their genes are generally transcribed by RNA polymerase II and the transcripts 
can be spliced and polyadenylated. The primary transcript is referred to as pri-miRNA. The pri-miRNA is processed within the nucleus by an 
enzymatic complex containing the Drosha RNaseIII enzyme and the DiGeorge syndrome critical region gene 8 (DGCR8) protein. The result-
ing precursor miRNA (pre-miRNA) is then exported to the cytoplasm by exportin-5. In the cytoplasm, the pre-miRNa is cleaved by Dicer
in combination with the TAR RNA binding protein (TRBP). This yields an approximately 20-bp miRNA duplex, one strand of which is then 
selected to function as a mature miRNA, whereas the other strand is in most cases degraded. Mature miRNAs become part of a ribonucleo-
protein (RNP) complex, called micro-RNP (miRNP), or an miRNA-induced silencing complex (miRISC). The miRISC recognizes its target and 
binds in the 3’ untranslated region of the target mRNA. When perfect complementarity exists between miRNA and target sequence, the tar-
get RNA is degraded. Without a perfect match, the target is not cleaved but is deadenylated or its translation is repressed. AGO—argonaute.
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ment and function has been steadily growing. Recent years 
have seen a tremendous increase in the number of miRNAs
recognized as being either specifically expressed or at least
enriched in the mammalian nervous system [24,25].
Evidence for an involvement of miRNAs has been
found in many stages of the developing nervous system,
including neural patterning, neuronal specification, and
axonal path finding. miRNAs also seem to play a role in
mature neurons (eg, in synaptic plasticity).
miRNA function in brain development 
and neuron/glia differentiation
For investigating potentially neurodevelopmental func-
tions of miRNAs, researchers have mostly relied on two
strategies: 1) investigation of single miRNAs or 2) inter-
ference with miRNA biogenesis and thereby disruption of 
the entire cellular miRNA complement. Both approaches 
require caution, however—the former because miRNAs
often belong to subfamilies in which functional redun-
dancy cannot be excluded, and the latter because it can
usually not be determined to what extent additional
cellular functions are disrupted and in what way this
disruption contributes to the observed phenotype. For
example, mutations in the Drosophila Argonaute 1 pro-
tein (dAGO-1), a miRISC component that is essential for 
miRNA function, lead to a drastic reduction in neurons
and glial cells [26]. However, although a dysfunctional 
miRNA system is a very plausible explanation, an impact
on other functions of dAGO-1 cannot be entirely ruled
out. Despite such limitations, however, converging results
of a growing number of studies provide increasingly strong
evidence for a central involvement of neuronal miRNAs
in the development of the central nervous system (CNS).
As mentioned previously, one important aspect that
seems to be influenced by miRNAs is neural pattern-
ing (ie, the patterning of the embryonic CNS along its 
anterior-posterior, dorsal-ventral, and left-right axes).
The mechanisms behind neural patterning might involve
miRNAs on various levels. Development of the anterior-
posterior axis of the CNS, for example, is regulated by
homeobox (Hox) genes, which are in turn targeted by
miRNAs [27,28]. Studies in zebrafish deficient in the Dicer 
protein (and therefore devoid of functional miRNAs)
revealed organizational defects during the formation of 
the embryonic neural plate and during its transformation
into the neural tube in the knockout animals [29••].
Beyond their potential role in basic structural organiza-
tion of the CNS, evidence is growing that miRNAs function 
in neuronal differentiation. The most detailed investigation
of miRNA influence on cell fate and identity has been car-
ried out on the main chemosensory neurons for chemotactic
reactions to water-soluble attractants (ASE neurons) in C.
elegans. These receptor neurons have the ability to spatial-
ize inputs based on the expression of distinct chemoreceptor
collectives defined during development. This difference in 
cell identity is based on the interaction of two miRNAs
(lsy-6 and miR-273) and their transcription factor targets
in a double-negative feedback loop [30–32]. In mice, the
miRNAs miR-9 and miR-124a have been implicated in the
decision of neural precursors between differentiation into
neurons and assumption of a glial phenotype [33]. Interest-
ingly, even in nonneuronal cells, expression of miR-124a
converts the overall gene-expression pattern to a neuronal
one [34••,35]. miR-124a decreases the levels of hundreds of 
nonneuronal transcripts, so that its introduction into HeLa
cells promotes a neuronal-like mRNA profile, whereas the 
transcriptional repressor, RE1 silencing transcription fac-
tor, has a reciprocal activity, inhibiting the expression of 
neuronal genes, including miR-124a, in nonneuronal cells
[36•]. A similar role for miR-133b in dopamine neuron
differentiation was recently reported. The authors first
observed that mice lacking Dicer in specific dopamine neu-
rons are born alive but later in life show a progressive loss
of neurons in combination with clinical features resem-
bling Parkinson’s disease. Therefore, Dicer seems essential
for neuronal survival, suggesting that the loss of miRNAs
may be involved in the development and/or progression of 
Parkinson’s disease [37•,38]. In view of the fact that the 
transfer of cellular-derived small RNAs (including miR-
NAs) partially preserved the dopaminergic phenotype in
cell culture [37•], it is likely that the absence of miRNAs, 
and not the lack of other potential Dicer-related functions, 
is involved in the neurodegenerative process. Further inves-
tigations implicated a negative-feedback regulatory loop
between miR-133b and the transcription factor Pitx3 in the
regulation of dopaminergic neuron differentiation [37•].
Beyond proper cell differentiation, axonal path finding
is mandatory for the establishment of functional circuitry 
in the nervous system during neural development. The first 
indications for an involvement of miRNAs were discovered
in zebrafish, where abnormalities in axon guidance were
observed in association with Dicer defects [29••]. These find-
ings were corroborated by a study in rat cell cultures showing 
that developing axons contain functional miRISCs [39]. 
Another important aspect of CNS development is the
massive loss of glia and neurons, which can range from
20% to 80% of differentiated cells, depending on the
brain region. Degeneration of these cells by programmed
cell death (apoptosis) accompanies neurogenesis and the 
expansion of brain size caused by the enlargement of 
neuronal cell bodies, myelination, expansion of dendritic
trees, secretion of the extracellular matrix, and blood ves-
sel arborization in the growing brain. Apoptotic processes
are strongly influenced by miRNAs, and even though the
bulk of the experimental evidence in this respect has been
obtained by cancer research [40], it leaves little doubt that
miRNAs also play a role in the developmental sequences 
that shape the mammalian brain.
miRNAs in synaptic plasticity
miRNAs are expressed in the fully differentiated neu-
rons of the mature brain (in many cases at comparatively
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high levels), and a central feature that might be subject 
to miRNA regulation is the control of plasticity. Synap-
tic plasticity has two distinct phases: an early phase that
is independent of protein synthesis and a late phase that
is long term and requires protein synthesis [41]. Many
investigations have argued strongly for the role of local
translation within dendrites in the establishment of long-
term plasticity [42–45]. Given the involvement of miRNAs
in translation regulation, long-term plasticity is conceiv-
ably where miRNA-mediated modulation has its greatest 
effect on brain function. In a very recent study focusing on
the separate quantification of microRNAs in the neuritic
and somatic compartments, a small number of miRNAs
were found to be relatively enriched in the dendrite [46]. 
A model for miRNA-mediated effects at the synapse has
been proposed [47], suggesting an influence of miRNAs on
transcripts whose translation is dependent, for example,
on stimulation of the ionotropic glutamate receptors by
glutamate. However, all models of miRNA involvement
in synaptic plasticity to date remain speculative and are
shrouded by the limited knowledge of mRNA routing from
the nucleus to distinct cytoplasmic destinations.
miRNAs and the circadian clock
In mammals, the master circadian clock resides in the
suprachiasmatic nuclei (SCN) of the hypothalamus and
keeps a roughly 24-hour cycle that is similar in the physi-
ologic processes of nearly all organisms. The circadian
rhythm is under the endogenous control of clock genes but
can respond to external cues (primarily daylight). Numer-
ous complex human behaviors, such as understanding
speech or performing music, depend on the ability of the
brain to determine time, and evidence for an involvement
of clock genes in mental diseases is mounting [48].
At the molecular level, the SCN clock has been
modeled as interlocking transcriptional feedback loops
that drive rhythmic expression of critical clock compo-
nents. Cheng et al. [49,50] recently discovered that two 
miRNAs might modulate the intrinsic pacemaker activ-
ity and resetting capacity of the SCN. The authors first
found that the transcription of miR-132 and miR-219 was
under the control of the cyclic adenosine monophosphate
(cAMP) response element–binding protein (CREB), the
transcription factor mediating gene expression that is
elicited by light stimulation in the SCN. In addition, miR-
219 was also identified as the target of another critical
element of the transcriptional network governing intrinsic
circadian rhythm, the transcription factor CLOCK. The
transcriptional regulation of these two miRNAs by CREB
and CLOCK was then substantiated by their rhythmic
expression within SCN and the light induction of miR-
132 expression. To explore the physiologic role of the two
miRNAs in setting the circadian clock, they were knocked
out in the mouse SCN and it was shown that miR-219 can 
regulate the length of the circadian day, whereas mir-R32 
acts as a feedback inhibitor of light-induced clock reset-
ting [49]. In the search for potential mechanisms by which
miR-219 and miR-132 modulate the circadian clock,
Cheng and Obrietan [50] identified 28 and 42 poten-
tial targets respectively, by applying a bioinformatics
approach. Two of these, the regulatory factor X4 (RFX4) 
for miR-132 and the suprachiasmatic nucleus oscillatory 
protein (SCOP) for miR-219, were experimentally con-
firmed [49]. The observation that several putative miR-132 
and miR-219 targets encode ion channels, together with
the recent work implicating cellular excitability in the 
generation of circadian rhythm, prompted the authors to
speculate about the roles of miR-132 and miR-219 in cel-
lular excitability, which could indeed be corroborated by
overexpression experiments in cultured cortical neurons
[49]. Finally, the link between the two miRNAs and core 
clock timing processes was established by the demonstra-
tion of their ability to augment the CLOCK-dependent, 
BMA1-dependent, and depolarization-dependent expres-
sion of mPer1 in cultured cells as well as in transgenic 
mice. Taken together, the available evidence strongly sug-
gests a central involvement of the miRNA pathway in the
control of circadian rhythm. Still, future studies will have 
to substantiate these findings and provide answers to the
questions of if and how miRNAs contribute to disease-
related aspects of the circadian clock.
miRNA and Human Diseases
The vast majority of data associating miRNAs with human
diseases came from cancer-related studies. In the past few 
years, a number of miRNAs have been implicated in the
regulation of cancer-relevant pathways, such as prolif-
eration and apoptosis, and several miRNAs have been
identified that act as either tumor suppressors or onco-
genes. The role of miRNAs in tumorigenesis, including
miRNA deregulation in brain tumors, has been extensively
reviewed [51•,52]. We focus on the contribution of the 
miRNA pathway to the etiopathology of brain disorders.
The first neurologic disorder linked with the miRNA
pathway was fragile X syndrome, the most common form
of inherited mental retardation, with an estimated preva-
lence of 1 in 4000 male individuals and 1 in 8000 female
individuals. Fragile X syndrome clinically manifests with
moderate to severe mental retardation, macroorchidism,
and distinct facial features and is caused by loss of FMR1
gene function. In most cases, the causative mutation is
the unstable expansion of a CGG repeat in the 5b UTR of 
FMR1, which results in hypermethylation of the FMR1
promoter and thus in transcriptional silencing [53,54].
The product of FMR1 is FMRP, an RNA-binding pro-
tein associated with polyribosomes as part of an mRNA
RNP (mRNP). FMRP can act as a negative regulator of 
translation within and at the base of dendritic spines. The 
first evidence of a link between FMRP and the miRNA
pathway came from the studies of protein components
of Drosophila FMRP (dFMRP). These components con-
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tained a complex that identified dFMRP as a component
of miRISC and revealed specific interactions between
dFMRP and two functional miRISC proteins, dAGO-2
and Dicer. Subsequent work in mammalian cells showed 
that in addition to Dicer and dAGO-2, dFMRP was also 
associated with endogenous miRNA [55]. Therefore,
it has been proposed that FMRP regulates a specific set
of mRNAs via the miRNA pathway. This hypothesis
was further supported by a study that demonstrated the
genetic interactions between dFMRP and dAGO-1 [56].
In that study, increased apoptosis caused by overexpres-
sion of dFMRP was largely suppressed by heterozygous 
loss of dAGO-1, whereas the synaptic overgrowth at the
neuromuscular junction due to the absence of dFMRP 
was exacerbated by heterozygous loss of dAGO-1. This
modulation of dFMRP-mediated translational regulation
by an miRISC component directly implicates the potential
role of the miRNA pathway in fragile X syndrome. 
FMRP and AGO were the first proteins to be estab-
lished as translational repressors. However, in recent work
by Vasudevan et al. [19••], AGO-2 and fragile X mental 
retardation–related protein1 (FXR1) were shown to act 
as translational activators via the miRNA pathway under
cell cycle arrest. In this context, it will be interesting to 
see whether FMRP can form similar complexes with a
positive-effect mRNA translation, and if so, whether this
also contributes to the etiology of fragile X syndrome.
Given the involvement of the miRNA pathway in frag-
ile X syndrome, it is intriguing to investigate the potential 
role of miRNA dysregulation in the disease pathogenesis
of mental retardation in general. For this purpose, we
screened 13 known brain-expressed X-chromosomal
miRNAs in a cohort of 464 patients with nonsyndromic
X-linked mental retardation and found four nucleotide
changes in three different miRNA genes [57]. Of the four
changes, which are all located outside the mature miRNA
sequences, one change found in miR-222 is close to the
Drosha processing site and might influence miRNA pro-
cessing under certain conditions. Interestingly, miR-222 is
also part of a 1.27-Mb deletion that is likely to be respon-
sible for mental retardation [58]. 
Although changes in miRNA genes can affect process-
ing efficiency or alter target specificity, genetic variation of 
miRNA target sequences in the 3b UTR could also influ-
ence the interaction between miRNAs and their targets. 
The first example of rare variants identified in miRNA tar-
get sequences came from the study of Tourette’s syndrome,
where an identical variant in the 3b UTR of the candidate
gene SLIT and Trk-like (SLITRK1) was found in two 
unrelated patients but was absent in 3600 control chromo-
somes. This rare variant was located in a predicted binding
site for mir-189, an miRNA expressed in the brain region
implicated in Tourette’s syndrome. More importantly, a
luciferase reporter assay suggested that the predicted site
was indeed functional and that the variant strengthened 
the interaction between SLITRK1 and mir-189 [59•].
Parkinson’s disease (PD) is a common neurodegenera-
tive disorder that is caused by a gradual loss of midbrain
dopaminergic neurons (DNs). As mentioned previously,
the observation that mice with a conditional deletion of 
Dicer in postmitotic midbrain DNs exhibited a PD-like
phenotype prompted Kim et al. [37•] to identify the dif-
ferentially expressed miRNAs between the midbrain of 
PD patients and that of controls. miR-133b turned out to
be specifically enriched in the midbrain from normal indi-
viduals but to be deficient in samples from PD patients.
This result, however, contradicts their finding that miR-
133b suppressed the full differentiation of DNs in cell
culture and suggests an additional role of miR-133b in
DN function and the pathology of PD, which still needs 
further elaboration [37•]. Recently, miRNA dysregula-
tion was studied in another neurodegenerative disorder,
Huntington’s disease (HD) [60]. HD is caused by a CAG 
expansion in the gene encoding the huntington protein,
and patients with HD show progressive loss of cortical
and striatal neurons associated with choreic movement
and dementia. It was found that huntington interacts with
REST and that mutant huntington inhibits the interaction,
leading to a deregulation of the REST target [61]. Starting 
with the identification of miRNA targets of REST, John-
son et al. [60] measured the expression of these potential
targets in the cortex of the mouse model of HD. Com-
pared with that in control mice, the expression of four
miRNAs (miR-28a, miR-124a, miR-132, and miR-135b)
was significantly reduced in HD mice, and in particular
the reduced expression of miR-124a was reflected by
an upregulation of its mRNA targets. In a subsequent
study in human samples, only miR-132 was found to be
downregulated in HD patients, which led to the increased
expression of its mRNA target p250GAP [60]. The
authors claimed that miRNA dysregulation accompanies
HD and suggested a model in which enhanced levels of 
nuclear REST in HD neurons lead to changes in the neu-
ronal transcriptome both directly, via repression of target
gene expression, and indirectly, via regulation of neuronal
miRNA expression [60].
Schizophrenia is a common brain disorder that affects 
approximately 1% percent of the general population [62].
To search for the candidate miRNAs involved in the etio-
pathology of this disease, Perkins et al. [63] compared
the expression of miRNAs from postmortem prefrontal
cortex of individuals with schizophrenia with that of 
unaffected individuals. By using microarrays spotted with
probes against 265 human miRNAs (at a false discovery
rate of 5%), the authors found 16 miRNAs to be differen-
tially expressed: 15 showed decreased expression and one
showed higher expression in the schizophrenia patients as
compared with controls. For miRNAs residing in introns
of protein-coding genes, they observed that the ratios of 
microarray expression levels of miRNA versus mRNA (of 
the respective host gene) were significantly different for
four of the six hosted miRNAs distinguished by schizo-
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phrenia [63]. Therefore the authors hypothesized that the
downregulation of miRNAs they observed is due to altered
miRNA biogenesis rather than altered transcription of pri-
miRNA. This is in keeping with the speculation that the 
potential involvement of the DiGeorge critical region gene
8 encoded protein (an RNA-binding protein that assists
Drosha in the processing of miRNAs) in schizophrenia is
via its regulation of miRNA biogenesis [63]. 
Therapeutic Potential of the miRNA System
Given the emerging evidence that miRNAs regulate
pathways that are involved in various disease etiologies,
researchers are now starting to look at the potential of 
miRNA-based therapeutics. At present, there are two strat-
egies for the development of miRNA-based therapeutics.
The first is to suppress endogenous miRNAs. This
can be achieved by using chemically modified antisense 
oligonucleotides complementary to mature miRNAs, 
such as 2b-O-methyl oligoribonucleotides (2-O-Me-
RNA), which have been successfully used for inhibiting
miRNA function in mammalian cell cultures. Similar 
results have been obtained in a number of mouse tis-
sues by intravenous or direct injection of antagomir, a
cholesterol-conjugated 2-O-Me-RNA with two or three 
phosphorothioate modifications on each end [64,65].
An alternative approach based on the same strategy
uses decoy mRNAs, which are also known as miRNA
sponges. These are transcripts expressed from strong
promoters, bearing multiple tandem binding sites of 
a given miRNA of interest. Inclusion of a central mis-
match at the AGO-2 cleavage site prevents degradation 
of the miRNA sponge and enables it to stably associate
with the target miRNA [66]. In cell cultures, the authors 
showed that their miRNA sponge was at least as effec-
tive as chemically modified antisense oligonucleotides. 
The second miRNA-based therapeutic strategy 
involves either restoring expression of miRNAs, which
is reduced in disease-associated tissues, or augmenting
the naturally occurring miRNA in targeting aberrant 
transcripts for silencing. Because miRNAs are chemically 
identical to small interfering RNAs (siRNAs), this strat-
egy will face the same challenges currently encountered 
by siRNA-based therapeutics, such as the problem of effi-
cient systematic delivery to different tissues or off-target
effects [67]. However, all the methods developed in the
siRNA field can also easily be used to solve problems in
the therapeutic application of miRNAs. The rapid pace in
this area of research raises the hope for successful employ-
ment of small RNAs in the treatment of human diseases 
in the future.
Conclusions
The study of miRNAs has revealed that they form a fam-
ily that is much larger than originally assumed and that 
they contribute to the regulation of a large proportion
of protein-coding transcripts. In order to understand the
complexity of this regulatory network, future research 
will have to go beyond single candidate validation and
ultimately will require genomic and proteomic studies.
The available evidence for a central role of the miRNA 
pathway in neuronal development and function is,
however, already compelling, and the first steps toward 
elucidating the involvement of miRNAs in the etiology of 
human cognitive disorders have been made. The coming
years will, in all likelihood, see a continuation of the rapid
development in miRNA research, and one is tempted to 
hope that RNA interference–based therapies are not too 
far beyond the horizon. 
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